HORMON RESEPTÖR POZİTİF, HER-2 NEGATİF METASTATİK MEME KANSERLİ HASTALARDA CDK4/6 İNHİBİTÖRÜ TEDAVİSİ ÖNCESİ SİSTEMİK İMMÜN İNFLAMASYON İNDEKSLERİNİN VE PROGNOSTİK NUTRİSYONEL İNDEKSİN PROGNOSTİK ÖNEMİ

Abstract Purpose: As systemic inflammatory indices and prognostic nutritional index are associated with poor prognosis in many tumor types, the goal of the present study was to ascertain their effect along with the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte ratio, C-reactive protein/albumin ratio, and systemic inflammatory response index on the progression-free survival (PFS) and overall survival (OS) of hormone receptor-positive HER2-negative (HR+/HER2−) metastatic breast cancer patients before CDK4/6 inhibitor treatment. Materials and Method: The medical records of 79 patients with HR+/HER2− metastatic breast cancer who presented at the Medical Oncology Outpatient Clinic between January 2018 and May 2022 were retrospectively analyzed to gather relevant data measured before CDK4/6 inhibitor treatment in order to establish the effect of key markers on their PFS and OS. Results: The median age of the participating patients, 70 (88.6%) of whom were postmenopausal, was 53 years (range 26−80 years). While 68 patients (86.1%) had a 0 performance score, 10 (12.7%) developed metastases during adjuvant endocrine therapy. Factors affecting PFS were age